Related Experiment Videos
Studies on segmented polyetherurethane for biomedical application: effects of composition and hard-segment content on
1Union Chemical Laboratories (UCL), Industrial Technology Research Institute (ITRI), Hsinchu, Taiwan, Republic of China.
Journal of Biomedical Materials Research
|August 11, 1998
Summary
Segmented polyetherurethane (SPEU) materials exhibit good biocompatibility. Lower hard-segment content SPEU shows reduced platelet adhesion, making it suitable for biomedical uses.
Area of Science:
- Biomaterials Science
- Polymer Chemistry
- Biocompatibility Testing
Background:
- Segmented polyetherurethanes (SPEUs) are advanced polymers with tunable properties.
- Polytetramethylene oxide (PTMO) is a key component in SPEU synthesis.
- Understanding SPEU's interaction with biological systems is crucial for medical applications.
Purpose of the Study:
- To synthesize and characterize PTMO-based SPEUs with varying hard-segment contents.
- To evaluate the biocompatibility and hemocompatibility of these SPEUs.
- To determine the influence of hard-segment content and PTMO molecular weight on SPEU performance.
Main Methods:
- Synthesis of SPEU materials using PTMO (Mw 1000 and 2000) with varied hard-segment percentages.
- Static contact angle measurements to assess surface hydrophilicity.
- Hemolysis and cytotoxicity assays (ISO 10993 standards).
- In vitro cell culture studies using L-929 cell lines for attachment and proliferation.
- In vitro platelet adhesion tests.
- Ex vivo canine artery-artery (A-A) and arterio-venous (A-V) shunting tests.
Main Results:
- Higher hard-segment content SPEUs demonstrated increased hydrophilicity (lower contact angle).
- All synthesized SPEUs were found to be non-hemolytic and non-cytotoxic.
- SPEUs with higher hard-segment content showed enhanced cell attachment and proliferation.
- Lower hard-segment content SPEUs exhibited significantly reduced platelet adhesion in vitro and ex vivo.
- SPEUs derived from PTMO 1000 generally outperformed those from PTMO 2000 in blood compatibility.
Conclusions:
- PTMO-based SPEUs are non-toxic and suitable for biomedical applications.
- Optimizing hard-segment content is key to balancing cell interaction and blood compatibility.
- SPEUs with lower hard-segment content show superior hemocompatibility, indicated by reduced platelet adhesion.
- PTMO molecular weight influences blood compatibility, with lower molecular weight (PTMO 1000) yielding better results.